Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATR-258
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atrogi Reports Positive Data from First-in-Class Diabetes Treatment
Details : ATR-258 binds to the beta-2-adrenoceptor to facilitate glucose transportation into skeletal muscle, lowering blood glucose levels and positively affecting several organs in Type 2 diabetes.
Product Name : ATR-258
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2024
Lead Product(s) : ATR-258
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable